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purpose
Previously published guidelines are available that provide
comprehensive recommendations for detecting and prevent-
ing healthcare-associated infections (HAIs). The intent of this
document is to highlight practical recommendations in a con-
cise format designed to assist acute care hospitals in imple-
menting and prioritizing their central line–associated blood-
stream infection (CLABSI) prevention efforts. This document
updates “Strategies to Prevent Central Line–Associated
Bloodstream Infections in Acute Care Hospitals,”1 published
in 2008. This expert guidance document is sponsored by the
Society for Healthcare Epidemiology of America (SHEA) and
is the product of a collaborative effort led by SHEA, the
Infectious Diseases Society of America (IDSA), the American
Hospital Association (AHA), the Association for Professionals
in Infection Control and Epidemiology (APIC), and The Joint
Commission, with major contributions from representatives
of a number of organizations and societies with content ex-
pertise. The list of endorsing and supporting organizations
is presented in the introduction to the 2014 updates.2
section 1: rationale and statements
of concern
I. Patients at risk for CLABSIs in acute care facilities
A. Intensive care unit (ICU) population: the risk of CLABSI
in ICU patients is high. Reasons for this include the
frequent insertion of multiple catheters, the use of spe-
cific types of catheters that are almost exclusively inserted
in ICU patients and associated with substantial risk (eg,
pulmonary artery catheters with catheter introducers),
and the fact that catheters are frequently placed in emer-
gency circumstances, repeatedly accessed each day, and
often needed for extended periods of time.3,4
B. Non-ICU population: although the primary focus of
attention over the last 2 decades has been the ICU set-
ting, the majority of CLABSIs occur in hospital units
outside the ICU or in outpatients.5-10
C. Infection prevention and control efforts should include
other vulnerable populations, such as patients receiving
hemodialysis through catheters,11 intraoperative pa-
tients,12 and oncology patients.
D. Besides central venous catheters (CVCs), peripheral ar-
terial catheters also carry a risk of infection.3
II. Outcomes associated with hospital-acquired CLABSI
A. Increased length of hospital stay.13-17
B. Increased cost (the non-inflation-adjusted attributable
cost of CLABSIs has been found to vary from $3,700
to $39,000 per episode14,17-19).
III. Independent risk factors for CLABSI (in at least 2 pub-
lished studies)20-25
A. Factors associated with increased risk.
1. Prolonged hospitalization before catheterization
2. Prolonged duration of catheterization
3. Heavy microbial colonization at the insertion site
4. Heavy microbial colonization of the catheter hub
5. Internal jugular catheterization
6. Femoral catheterization in adults
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7. Neutropenia
8. Prematurity (ie, early gestational age)
9. Reduced nurse-to-patient ratio in the ICU26,27
10. Total parenteral nutrition
11. Substandard catheter care (eg, excessive manipula-
tion of the catheter)
12. Transfusion of blood products (in children)
B. Factors associated with reduced risk.
1. Female sex
2. Antibiotic administration22,28
3. Minocycline-rifampin-impregnated catheters29,30
section 2: background—strategies
to detect clabsi
I. Surveillance protocol and definition of CLABSIs
A. Use consistent surveillance methods and definitions to
allow comparison to benchmark data.
B. Refer to the National Healthcare Safety Network (NHSN)
Manual: Patient Safety Component Protocol for infor-
mation on the appropriate surveillance methodology, in-
cluding information about blood specimen collection,
and for surveillance definitions of CLABSIs. The relevant
sections of the manual are “Identifying Healthcare-
Associated Infections (HAI) in NHSN,” “Device-Asso-
ciated Module: Methodology,” and “Device-Associated
Module: Central Line–Associated Bloodstream Infection
(CLABSI) Event.”31
1. Recent data suggest that interrater reliability using
NHSN definitions is lower than expected.32-34 This may
also affect the reliability of public reporting. Addition-
ally, the NHSN surveillance definition for CLABSI is
different from the clinical definition for catheter-
related bloodstream infection.35
section 3: background—strategies
to prevent clabsi
I. Existing guidelines and recommendations
A. Several governmental, public health, and professional
organizations have published evidence-based guidelines
and/or implementation aids regarding the prevention
of CLABSI, including the following:
1. The Healthcare Infection Control Practices Advisory
Committee (HICPAC), Centers for Disease Control
and Prevention36,37
2. The Institute for Healthcare Improvement38
3. The Agency for Healthcare Research and Quality39
4. The American Pediatric Surgical Association Out-
comes and Clinical Trials Committee40
5. The Joint Commission41
6. APIC42
7. The Infusion Nurses Society43
B. The recommendations in this document focus on CVCs
unless noted otherwise. These recommendations
1. Are not stratified on the basis of catheter type (eg,
tunneled, implanted, cuffed, noncuffed catheter, and
dialysis catheter) and
2. May not be applicable for prevention of bloodstream
infections with other intravascular devices.
II. Infrastructure requirements include the following:
A. An adequately staffed infection prevention and control
program responsible for identifying patients who meet
the surveillance definition for CLABSI.
B. Information technology to collect and calculate cathe-
ter-days as a denominator when computing rates of
CLABSI and patient-days to allow calculation of CVC
utilization. Catheter-days from information systems
should be validated against a manual method, with a
margin of error no greater than 5%.
C. Resources to provide appropriate education and
training.
D. Adequate laboratory support for timely processing of
specimens and reporting of results.
section 4: recommended strategies
for clabsi prevention
Recommendations are categorized as either (1) basic practices
that should be adopted by all acute care hospitals or (2)
special approaches that can be considered for use in lo-
cations and/or populations within hospitals when CLABSIs
are not controlled by use of basic practices. Basic practices
include recommendations where the potential to impact
CLABSI risk clearly outweighs the potential for undesirable
effects. Special approaches include recommendations where
the intervention is likely to reduce CLABSI risk but where
there is concern about the risks for undesirable outcomes,
where the quality of evidence is low, or where evidence
supports the impact of the intervention in select settings
(eg, during outbreaks) or for select patient populations.
Hospitals can prioritize their efforts by initially focusing on
implementing the prevention approaches listed as basic
practices. If CLABSI surveillance or other risk assessments
suggest that there are ongoing opportunities for improve-
ment, hospitals should then consider adopting some or all
of the prevention approaches listed as special approaches.
These can be implemented in specific locations or patient
populations or can be implemented hospital-wide, depend-
ing on outcome data, risk assessment, and/or local require-
ments. Each infection prevention recommendation is given
a quality-of-evidence grade (see Table 1).
Note that some of the following measures have been com-
bined into a “prevention bundle” that focuses on catheter
insertion (eg, measures B.2, B.3, B.6, B.7, and C.3).44-46 Nu-
merous studies have documented that use of such bundles is
effective, sustainable, and cost-effective in both adults and
children.47-50 Bundles are most likely to be successful if im-
plemented in a previously established patient safety culture,
and their success depends on adherence to individual mea-
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table 1. Grading of the Quality of Evidence
Grade Definition
I. High Highly confident that the true effect lies close to that of the estimated size and direction of the
effect. Evidence is rated as high quality when there is a wide range of studies with no major
limitations, there is little variation between studies, and the summary estimate has a narrow
confidence interval.
II. Moderate The true effect is likely to be close to the estimated size and direction of the effect, but there is
a possibility that it is substantially different. Evidence is rated as moderate quality when there
are only a few studies and some have limitations but not major flaws, there is some variation
between studies, or the confidence interval of the summary estimate is wide.
III. Low The true effect may be substantially different from the estimated size and direction of the effect.
Evidence is rated as low quality when supporting studies have major flaws, there is important
variation between studies, the confidence interval of the summary estimate is very wide, or
there are no rigorous studies, only expert consensus.
note. Based on Grades of Recommendation, Assessment, Development, and Evaluation (GRADE)257 and the
Canadian Task Force on Preventive Health Care.258
sures.51 However, recent data suggest that not all components
of bundles may be necessary to achieve an effect on CLABSI
rates.52 After catheter insertion, maintenance bundles have
been proposed to ensure optimal catheter care.53 More data
are needed to determine which components of the mainte-
nance bundle are essential in reducing risk.54,55
I. Basic practices for preventing and monitoring CLABSI:
recommended for all acute care hospitals
A. Before insertion
1. Provide easy access to an evidence-based list of in-
dications for CVC use to minimize unnecessary CVC
placement (quality of evidence: III).
2. Require education of healthcare personnel involved
in insertion, care, and maintenance of CVCs about
CLABSI prevention (quality of evidence: II).56-60
a. Include the indications for catheter use, appropri-
ate insertion and maintenance, the risk of CLABSI,
and general infection prevention strategies.
b. Ensure that all healthcare personnel involved in
catheter insertion and maintenance complete an
educational program regarding basic practices to
prevent CLABSI before performing these duties.61,62
Periodic retraining with a competency assessment
may be of benefit.63
c. Ensure that any healthcare professional who inserts
a CVC undergoes a credentialing process (as es-
tablished by the individual healthcare institution)
to ensure their competency before independently
inserting a CVC.
d. Reeducate when an institution changes compo-
nents of the infusion system that requires a change
in practice (eg, when an institution’s change of the
needleless connector requires a change in nursing
practice).
e. Consider using simulation training for proper cath-
eter insertion technique.64-66
3. Bathe ICU patients over 2 months of age with a chlor-
hexidine preparation on a daily basis (quality of evi-
dence: I).67-70
a. In long-term acute care hospitals, daily chlorhex-
idine bathing may also be considered as a preven-
tive measure.71
b. The role of chlorhexidine bathing in non-ICU pa-
tients remains to be determined.72
c. The optimal choice of antiseptic agents is unre-
solved for children under 2 months of age. How-
ever, chlorhexidine is widely used in children under
2 months of age.73 A US survey found that in the
majority of neonatal ICUs (NICUs) chlorhexidine
products are used for catheter insertion in this age
group.74 For chlorhexidine gluconate (CHG)–based
topical antiseptic products, the Food and Drug Ad-
ministration recommends “use with care in pre-
mature infants or infants under 2 months of age;
these products may cause irritation or chemical
burns.” The American Pediatric Surgical Associa-
tion recommends CHG use but states that “care
should be taken in using chlorhexidine in neonates
and premature infants because of increased risk of
skin irritation and risk of systemic absorption.”40
Concerns in children under 2 months have been
noted elsewhere.75 Cutaneous reactions to CHG
have also been reported in extremely-low-birth-
weight neonates under 48 hours of age;76 however,
in a small pilot trial of neonates under 1,000 g and
at least 7 days of age, severe contact dermatitis did
not occur, although CHG was cutaneously ab-
sorbed.77 These findings have not been replicated
in a recent trial in neonates weighing more than
or equal to 1,500 g.78,79 Some institutions have used
chlorhexidine-containing sponge dressings for
CVCs79 and chlorhexidine for cleaning CVC in-
sertion sites in children in this age group with min-
imal risk of such reactions.40 Providers must care-
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fully weigh the potential benefit in preventing
CLABSI in children under 2 months and the risks
of CHG, recognizing that term and preterm infants
may have different risks. Alternative agents, such
as povidone-iodine or alcohol, can be used in this
age group.80
B. At insertion
1. Have a process in place to ensure adherence to in-
fection prevention practices at the time of CVC in-
sertion in ICU and non-ICU settings, such as a check-
list (quality of evidence: II).45,81,82
a. Ensure and document adherence to aseptic
technique.
i. Checklists have been suggested to ensure op-
timal insertion practices. If used, the docu-
mentation should be done by someone other
than the inserter.
ii. Observation of CVC insertion by a nurse, phy-
sician, or other healthcare personnel who has
received appropriate education (see above) to
ensure that aseptic technique is maintained.
iii. Such healthcare personnel should be empow-
ered to stop the procedure if breaches in aseptic
technique are observed.
2. Perform hand hygiene prior to catheter insertion or
manipulation (quality of evidence: II).83-87
a. Use an alcohol-based waterless product or anti-
septic soap and water.
i. Use of gloves does not obviate hand hygiene.
3. Avoid using the femoral vein for central venous access
in obese adult patients when the catheter is placed
under planned and controlled conditions (quality of
evidence: I).28,88-90
a. Additional factors may influence the risk of CLABSI
in patients with femoral vein catheters.91,92
b. Femoral vein catheterization can be done without
general anesthesia in children and has not been
associated with an increased risk of infection in
this population.93
c. Controversy exists regarding infectious and non-
infectious complications associated with different
short-term CVC access sites.89,94 The risk and ben-
efit of different insertion sites must be considered
on an individual basis with regard to infectious and
noninfectious complications (eg, patients with jug-
ular access may have a higher infection risk if they
have a concurrent tracheostomy95).
d. Do not use peripherally inserted CVCs (PICCs) as
a strategy to reduce the risk of CLABSI.
i. The risk of infection with PICCs in ICU patients
approaches that of CVCs placed in the subcla-
vian or internal jugular veins.96,97
ii. The majority of CLABSIs due to PICCs occur
in non-ICU settings.98 The PICC-associated
CLABSI risk may be different outside the ICU.
4. Use an all-inclusive catheter cart or kit (quality of
evidence: II).45
a. A catheter cart or kit that contains all necessary
components for aseptic catheter insertion has to
be available and easily accessible in all units where
CVCs are inserted.
5. Use ultrasound guidance for internal jugular catheter
insertion (quality of evidence: II).99
a. Ultrasound-guided internal jugular vein catheter-
ization reduces the risk of CLABSI and of non-
infectious complications of CVC placement.100
6. Use maximum sterile barrier precautions during CVC
insertion (quality of evidence: II).101-107
a. Use maximal sterile barrier precautions.
i. A mask, cap, sterile gown, and sterile gloves are
to be worn by all healthcare personnel involved
in the catheter insertion procedure.
ii. The patient is to be covered with a large (“full-
body”) sterile drape during catheter insertion.
b. These measures must also be followed when ex-
changing a catheter over a guidewire.
c. A prospective randomized study in surgical patients
showed no additional benefit for maximal sterile
barrier precautions;105 nevertheless, most available
evidence suggests risk reduction with this inter-
vention.
7. Use an alcoholic chlorhexidine antiseptic for skin
preparation (quality of evidence: I).108-111
a. Before catheter insertion, apply an alcoholic chlor-
hexidine solution containing more than 0.5% CHG
to the insertion site.112
i. The antiseptic solution must be allowed to dry
before making the skin puncture.
C. After insertion
1. Ensure appropriate nurse-to-patient ratio and limit
the use of float nurses in ICUs (quality of evidence:
I).26,27,113,114
a. Observational studies suggest that there should be
a nurse-to-patient ratio of at least 1 to 2 in ICUs
where nurses are managing patients with CVCs and
that the number of float nurses working in the ICU
environment should be minimized.
2. Disinfect catheter hubs, needleless connectors, and
injection ports before accessing the catheter (quality
of evidence: II).115-119
a. Before accessing catheter hubs, needleless con-
nectors, or injection ports, vigorously apply me-
chanical friction with an alcoholic chlorhexidine
preparation, 70% alcohol, or povidone-iodine. Al-
coholic chlorhexidine may have additional residual
activity compared with alcohol for this purpose.120
b. Apply mechanical friction for no less than 5 seconds
to reduce contamination.121,122 It is unclear whether
this duration of disinfection can be generalized to
needleless connectors not tested in these studies.
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c. Monitor compliance with hub/connector/port dis-
infection since approximately half of such catheter
components are colonized under conditions of
standard practice.117,121
3. Remove nonessential catheters (quality of evidence:
II).123,124
a. Assess the need for continued intravascular access
on a daily basis during multidisciplinary rounds.
Remove catheters not required for patient care.
b. Audits to determine whether CVCs are routinely
removed after their intended use may be help-
ful.125,126 Both simple and multifaceted interventions
are effective at reducing unnecessary CVC use.127,128
4. For nontunneled CVCs in adults and children, change
transparent dressings and perform site care with a
chlorhexidine-based antiseptic every 5–7 days or im-
mediately if the dressing is soiled, loose, or damp;
change gauze dressings every 2 days or earlier if the
dressing is soiled, loose, or damp (quality of evidence:
II).129-131
a. Less-frequent dressing changes may be used for
selected NICU patients to reduce the risk of cath-
eter dislodgement.
b. If there is drainage from the catheter exit site, use
gauze dressings instead of transparent dressings
until drainage resolves.
5. Replace administration sets not used for blood, blood
products, or lipids at intervals not longer than 96
hours (quality of evidence: II).132,133
a. The optimal replacement intervals of intermittently
used administration sets are currently unresolved.
6. Use antimicrobial ointments for hemodialysis cath-
eter-insertion sites (quality of evidence: I).134-140
a. Polysporin “triple” (where available) or povidone-
iodine ointment should be applied to hemodialysis
catheter insertion if compatible with the catheter
material.
i. Certain manufacturers have indicated that the
glycol constituents of ointments should not be
used on their polyurethane catheters.
b. Mupirocin ointment should not be applied to the
catheter-insertion site due to the risks of facilitating
mupirocin resistance and the potential damage to
polyurethane catheters.
7. Perform surveillance for CLABSI in ICU and non-
ICU settings (quality of evidence: I).6,7,141,142
a. Measure the unit-specific incidence of CLABSI
(CLABSIs per 1,000 catheter-days) and report the
data on a regular basis to the units, physician and
nursing leadership, and hospital administrators
overseeing the units.
b. Compare CLABSI incidence with historical data for
individual units and with national rates (ie,
NHSN143).
c. Audit surveillance as necessary to minimize vari-
ation in interobserver reliability.32,33
d. Surveillance for CLABSI outside the ICU setting
requires additional resources.144 Electronic surveil-
lance is an option in these settings.145
II. Special approaches for preventing CLABSI
A number of special approaches are currently available
for use. Perform a CLABSI risk assessment before con-
sidering implementing any of these approaches, and take
potential adverse events and cost into consideration. Al-
though it is reasonable to evaluate the utility of technol-
ogy-based interventions when CLABSI rates are above the
institutional or unit-based threshold, this is also an op-
portunity to review practices and consider behavioral
changes that may be instituted to reduce CLABSI risk.
These special approaches are recommended for use in
locations and/or populations within the hospital with un-
acceptably high CLABSI rates despite implementation of
the basic CLABSI prevention strategies listed above. These
measures may not be indicated if institutional goals have
been consistently achieved.
1. Use antiseptic- or antimicrobial-impregnated CVCs in
adult patients (quality of evidence: I).29,30,146-152
a. The risk of CLABSI is reduced with some currently
marketed antiseptic-impregnated (eg, chlorhexidine–
silver sulfadiazine) catheters and antimicrobial-
impregnated (eg, minocycline-rifampin) catheters.
Use such catheters in the following instances.
i. Hospital units or patient populations have a
CLABSI rate above institutional goals despite
compliance with basic CLABSI prevention prac-
tices. Some evidence suggests that use of anti-
microbial CVCs may have no additional benefit
in patient care units that have already established
a low incidence of catheter infections.153
ii. Patients have limited venous access and a history
of recurrent CLABSI.
iii. Patients are at heightened risk of severe sequelae
from a CLABSI (eg, patients with recently im-
planted intravascular devices, such as a prosthetic
heart valve or aortic graft).
b. Monitor patients for untoward effects, such as
anaphylaxis.154
2. Use chlorhexidine-containing dressings for CVCs in
patients over 2 months of age (quality of evidence:
I).80,155-160
a. It is unclear whether there is additional benefit to
using a chlorhexidine-containing dressing if daily
chlorhexidine bathing is already established and vice
versa.
3. Use an antiseptic-containing hub/connector cap/port
protector to cover connectors (quality of evidence:
I).161-165
4. Use silver zeolite–impregnated umbilical catheters in
preterm infants (in countries where it is approved for
use in children; quality of evidence: II).166
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a. Observational studies suggest that other antimicro-
bial-impregnated catheters appear to be safe and hold
promise in pediatric ICU patients.167-169
5. Use antimicrobial locks for CVCs (quality of evidence:
I).170-175
a. Antibiotic locks are created by filling the lumen of
the catheter with a supratherapeutic concentration of
an antimicrobial solution and leaving the solution in
place until the catheter hub is reaccessed. Such an
approach can reduce the risk of CLABSI. Because of
concerns regarding the potential for the emergence
of resistance in exposed organisms, use antimicrobial
locks as a preventative strategy for the following:
i. Patients with long-term hemodialysis catheters.176
ii. Patients with limited venous access and a history
of recurrent CLABSI.
iii. Patients who are at heightened risk of severe se-
quelae from a CLABSI (eg, patients with recently
implanted intravascular devices, such as a pros-
thetic heart valve or aortic graft).
b. To minimize systemic toxicity, aspirate rather than
flush the antimicrobial lock solution after the dwell
time has elapsed.177-180 For additional guidance, see
the IDSA’s “Clinical Practice Guidelines for the Di-
agnosis and Management of Intravascular Catheter-
Related Infection.”35
6. Use recombinant tissue plasminogen activating factor
once weekly after hemodialysis in patients undergoing
hemodialysis through a CVC (quality of evidence: II).181
III. Approaches that should not be considered a routine part
of CLABSI prevention
1. Do not use antimicrobial prophylaxis for short-term or
tunneled catheter insertion or while catheters are in situ
(quality of evidence: I).182-186
a. Systemic antimicrobial prophylaxis is not recom-
mended.
2. Do not routinely replace central venous or arterial cath-
eters (quality of evidence: I).187-189
a. Routine catheter replacement is not recommended.
IV. Unresolved issues
1. Routine use of needleless connectors as a CLABSI pre-
vention strategy before an assessment of risks, benefits,
and education regarding proper use.190-194
a. Multiple devices are currently available, but the op-
timal design for preventing infections is unresolved.
The original purpose of needleless connectors was to
prevent needlestick injuries during intermittent use.
No data regarding their use with continuous infusions
are available.
2. Intravenous therapy teams for reducing CLABSI
rates.77,195
a. Studies have shown that an intravenous therapy team
responsible for insertion and maintenance of periph-
eral intravenous catheters reduces the risk of blood-
stream infections.196 However, few studies have been
performed regarding the impact of intravenous ther-
apy teams on CLABSI rates.
3. Surveillance of other types of catheters (eg, peripheral
arterial or venous catheters).3,4
a. Peripheral arterial catheters and peripheral venous
catheters are not included in most surveillance sys-
tems, although they are associated with risk of blood-
stream infection independent of CVCs.197,198 Future
surveillance systems may need to include bloodstream
infections associated with these types of catheters.
4. Estimating catheter-days for determining incidence
density of CLABSI.
a. Surveillance can be facilitated in settings with a lim-
ited workforce by estimating the number of catheter-
days.199-201
5. Use of silver-coated catheter connectors are associated
with reduced intraluminal contamination in ex vivo
catheters.202
a. There is a paucity of clinical evidence regarding the
risk reduction with their routine use or use of other
antimicrobial catheter connectors.
6. Standard, nonantimicrobial transparent dressings and
CLABSI risk.
a. A recent meta-analysis reported an association be-
tween CLABSI and transparent dressing use. How-
ever, the source studies for the meta-analysis report-
ing this association were of low quality.203
7. Impact of the use of chlorhexidine-based products on
bacterial resistance to chlorhexidine.
a. Widespread use of chlorhexidine-based products (eg,
use of chlorhexidine bathing, antisepsis, and dress-
ings) may promote reduced chlorhexidine suscepti-
bility in bacterial strains.204 However, testing for
chlorhexidine susceptibility is not standardized. The
clinical impact of reduced chlorhexidine susceptibility
in gram-negative bacteria is unknown.
section 5: performance measures
I. Internal reporting
These performance measures are intended to support
internal hospital quality improvement efforts205,206 and do
not necessarily address external reporting needs. The pro-
cess and outcome measures suggested here are derived
from published guidelines, other relevant literature, and
the opinion of the authors. Report process and outcome
measures to senior hospital leadership, nursing leadership,
and clinicians who care for patients at risk for CLABSI.
A. Process measures
1. Compliance with CVC insertion guidelines as doc-
umented on an insertion checklist.
a. Assess compliance with the checklist in all hospital
settings where CVCs are inserted (eg, ICUs, emer-
gency departments, operating rooms, radiology,
and general nursing units) and assign a healthcare
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personnel familiar with catheter care to this task.
i. For an example of a central catheter checklist,
see http://www.ihi.org/knowledge/Pages/Tools
/CentralLineInsertionChecklist.aspx.
b. Measure the percentage of CVC insertion proce-
dures in which compliance with appropriate hand
hygiene, use of maximal sterile barrier precautions,
and use of chlorhexidine-based cutaneous antisep-
sis of the insertion site is documented:
i. Numerator: number of CVC insertions that
have documented the use of all 3 interventions
(hand hygiene, maximal barrier precautions,
and chlorhexidine-based cutaneous antiseptic
use) performed at the time of CVC insertion.
ii. Denominator: number of all CVC insertions.
iii. Multiply by 100 so that the measure is expressed
as a percentage.
2. Compliance with documentation of daily assessment
regarding the need for continuing CVC access.
a. Measure the percentage of patients with a CVC
where there is documentation of daily assessment:
i. Numerator: number of patients with a CVC
who have documentation of daily assessment.
ii. Denominator: number of patients with a CVC.
iii. Multiply by 100 so that the measure is expressed
as a percentage.
3. Compliance with cleaning of catheter hubs and in-
jection ports before they are accessed (or compliance
with use of antiseptic-containing port protectors).
a. Assess compliance through observations of prac-
tice:
i. Numerator: number of times that a catheter
hub or port (or port protector) is observed to
be cleaned before being accessed.
ii. Denominator: number of times a catheter hub
or port (or port protector) is observed to be
accessed.
iii. Multiply by 100 so that the measure is expressed
as a percentage.
B. Outcome measures
1. CLABSI rate.
a. Use NHSN definitions.
i. Numerator: number of CLABSIs in each unit
assessed (using NHSN definitions).
ii. Denominator: total number of catheter-days in
each unit assessed (using NHSN definitions).
iii. Multiply by 1,000 so that the measure is ex-
pressed as the number of CLABSIs per 1,000
catheter-days.
iv. Risk adjustment: stratify CLABSI rates by type
of patient care unit.207-209
(a) Report comparisons based on historical data
and NHSN data, if available.143
II. External reporting
There are many challenges in providing useful infor-
mation to consumers and other stakeholders while pre-
venting unintended consequences of public reporting of
HAIs.210,211 Recommendations for public reporting of
HAIs have been provided by HICPAC,212 the Healthcare-
Associated Infection Working Group of the Joint Public
Policy Committee,213 and the National Quality Forum.214
A. State and federal requirements
1. Hospitals in states that have mandatory reporting re-
quirements for CLABSI must collect and report the
data required by the state.
2. For information on state and federal requirements,
contact your state or local health department.
B. External quality initiatives
1. Hospitals that participate in external quality initia-
tives or state programs must collect and report the
data required by the initiative or program.
2. Problems with interrater reliability may affect com-
parisons between different institutions.
section 6: examples of
implementation strategies
Accountability is an essential principle for preventing HAIs.
It provides the necessary translational link between science
and implementation. Without clear accountability, scientifi-
cally based implementation strategies will be used in an in-
consistent and fragmented way, decreasing their effectiveness
in preventing HAIs. Accountability begins with the chief ex-
ecutive officer and other senior leaders who provide the im-
perative for HAI prevention, thereby making HAI prevention
an organizational priority. Senior leadership is accountable
for providing adequate resources needed for effective imple-
mentation of an HAI prevention program. These resources
include necessary personnel (clinical and nonclinical), edu-
cation, and equipment (Table 2).
Insertion of CVCs is one of the most common procedures
performed at the patient’s bedside. The insertion procedure
represents only one aspect of the risk for CLABSI, with the
risk extending to all aspects of nursing care and maintenance
during the CVC dwell time. CLABSI prevention strategies
have expanded as new studies are published. Additionally,
experience with implementing these strategies is increasing.
This discussion will focus on strategies for engagement, ed-
ucation, execution, and evaluation of CLABSI prevention ef-
forts. Published literature and expert opinion form the basis
for the following recommendations.
I. Engage
The first step toward successful reduction of CLABSIs
is to engage both frontline and senior leadership cham-
pions in the process and outcome improvement plan.215
A. Develop a multidisciplinary team that sets goals, defines
the steps in the implementation process, and monitors
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table 2. Fundamental Elements of Accountability for Healthcare-Associated Infection Prevention
Senior management is responsible for ensuring that the healthcare system supports an infection prevention and control (IPC) pro-
gram that effectively prevents healthcare-associated infections (HAIs) and the transmission of epidemiologically important
pathogens
Senior management is accountable for ensuring that an adequate number of trained personnel are assigned to the IPC program and
adequate staffing of other departments that play a key role in HAI prevention (eg, environmental services)
Senior management is accountable for ensuring that healthcare personnel, including licensed and nonlicensed personnel, are ade-
quately trained and competent to perform their job responsibilities
Direct healthcare providers (such as physicians, nurses, aides, and therapists) and ancillary personnel (such as environmental service
and equipment processing personnel) are responsible for ensuring that appropriate IPC practices are used at all times (including
hand hygiene, standard and isolation precautions, and cleaning and disinfection of equipment and the environment)
Senior and unit leaders are responsible for holding personnel accountable for their actions
IPC leadership is responsible for ensuring that an active program to identify HAIs is implemented, that HAI data are analyzed and
regularly provided to those who can use the information to improve the quality of care (eg, unit staff, clinicians, and hospital
administrators), and that evidence-based practices are incorporated into the program
Senior and unit leaders are accountable for ensuring that appropriate training and educational programs to prevent HAIs are devel-
oped and provided to personnel, patients, and families
Personnel from the IPC program, the laboratory, and information technology departments are responsible for ensuring that systems
are in place to support the surveillance program
progress in achieving the goals. Regular team meetings
should be held.216
B. Focus on a culture of safety, which includes teamwork,
technical processes, and promotion of accountability for
prevention of CLABSI.
C. Make the problem real to all of those involved to in-
crease buy-in. One strategy to accomplish this is to
identify a patient in the unit who has suffered harm as
a result of developing a CLABSI217 and then share that
story with the team.
D. Identify and involve local champions. Engage infusion
nurses or vascular access specialists as team members.
Include formal (eg, medical or nursing directors, charge
nurses) and informal (eg, frontline) leaders.218 Local
champions increase the chance for success by engaging
and educating peers, thereby increasing buy-in and own-
ership by all involved.215 These champions can influence
the development of strategies that are a good match with
the unit culture. Frequent communication between
champions and frontline staff is imperative if concerns
are to be resolved and improvement sustained.215
E. Share the outcome data regularly with each unit. Data
can be represented as the monthly CLABSI rate and/or
the number of days since last infection.217 Consider re-
porting CLABSI rates as the standardized infection ratio
(SIR). Displaying a trend line is also useful.
F. Utilize peer networks. Voluntary peer networking be-
tween hospitals can promote and ensure compliance
with evidence-based practices. It also facilitates collab-
oration, performance evaluation, and accountability. All
can benefit from best practices being shared, and brain-
storming can be done to solve shared problems.219
II. Educate
A. Change in human behavior is the goal of educational
programs about CVC insertion, care, and maintenance.
Various educational methods and strategies have been
studied to reduce CLABSI. In general, these educational
interventions showed improvements in CLABSI rates;
however, more study is needed to clearly understand
the most effective teaching strategies, content taught,
length of presentation, and frequency for repeating the
program.220,221 Both extraluminal and intraluminal av-
enues for CVC infection should be addressed in the
educational plan.
B. Educational programs for all healthcare personnel in-
volved with the insertion and care of all types of CVCs
should address knowledge, critical thinking, behavior
and psychomotor skills, and attitudes and beliefs. Iden-
tifying and analyzing gaps in these areas leads to the
selection of measureable learning objectives, course
content, and corresponding appropriate teaching strat-
egies. The value of infection prevention should be em-
phasized through all education efforts.221,222
C. Adult learners employ multiple ways to learn; therefore,
multiple teaching strategies should be used. This in-
cludes self-directed study guides, instructor-led courses,
and small- and large-group discussions. The planning
group for the educational offering should have repre-
sentatives from multiple professions, including physi-
cians, nurse managers, staff nurses, infusion nurse spe-
cialists, and infection preventionists.223-225 The learner
should be actively involved with the teaching methods,
as lecture alone has been shown to be less effective with
retention of information and changes in behavior.226,227
Delivery methods should be chosen on the basis of the
learners’ needs and availability, along with the technical
capabilities of the facility. This includes printed learning
packages; audiovisual formats, such as slide presenta-
tions and videos; skills labs; journal clubs and nursing
grand rounds; and computer-, Internet-, or DVD-based
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packages of learning materials.58,224,228-231 Multiple deliv-
ery methods tailored to specific problems or issues and
given intermittently over time produce greater reduc-
tion in CLABSI than a single structured offering or
lecture.61,232
D. Other educational job aides should be readily accessible
in the clinical setting for quick reminders and rein-
forcement of the appropriate procedures. This includes
but is not limited to facility policies and procedures,
posters, fact sheets, small pocket cards, e-mail messages,
and messages via computer screen savers.233,234
E. To enhance patient safety, learning CVC insertion tech-
niques requires a structured educational program fo-
cusing on knowledge acquisition and performance of
insertions in a simulated environment, followed by su-
pervised performance on patients.43,235-237 A meta-anal-
ysis of 20 studies using simulation for CVC insertion
showed benefits in learner performance, knowledge,
and confidence.66 Simulation for CVC insertion in-
cludes use of anatomical models and computer-based
virtual reality.238 Other approaches have tried to sim-
ulate the “feel” of tissue puncture.239
F. All healthcare professionals should have documented
competency with CVC insertion, care, and maintenance
before being allowed to practice without direct super-
vision. A standardized competency assessment checklist
should be used to assess and document competency of
each individual performing CVC insertion and proce-
dures related to care and maintenance (eg, dressing
changes). Competency assessment checklists should be
evaluated for interrater reliability and validity. The pro-
fessional performing competency assessment of the
learner should be competent with the procedure being
assessed.220,240
G. Changes of products, devices, or technology used in the
insertion and care of CVCs require adequate device
training for all healthcare personnel expected to use the
product(s). This training follows a period of device
evaluation and its impact on CLABSI. Most device
manufacturers employ personnel with clinical experi-
ence to provide product training, and this resource
should not be overlooked.
H. Healthcare professionals using CVCs for infusion
should have documented competency with all proce-
dures, including but not limited to catheter stabiliza-
tion, catheter dressing changes, intravenous adminis-
tration set management, disinfection of needleless
connectors, accessing implanted ports, and flushing
and locking the CVC.43 This would involve demon-
stration of procedures in a simulation lab or in the
clinical setting while being observed by a qualified
professional.241,242
I. Assessment of educational programs includes the
learner’s satisfaction with the program, changes in
knowledge, and changes in work performance. Written
tests are the most common form of measurement; how-
ever, this is limited to knowledge acquisition only and
may produce anxiety in many adult learners. Other
forms of assessment include contributions to group dis-
cussions and observation of performance using simu-
lation. Measurement of healthcare professionals’ current
level of knowledge about CVC insertion and care can
provide valuable information for designing educational
programs.243,244
J. Prior to an educational program, there should be plan-
ning for transfer of the learning from the classroom to
the clinical setting. This includes patient care assign-
ments to allow for application of new knowledge and
practice of new skills, support and encouragement from
leaders and managers, and the ability to follow up on
issues or concerns that arise from clinical performance.
K. Education of the patient and/or family, as appropriate,
is required for all CVC care procedures (eg, hand hy-
giene, dressing changes, intravenous administration set
management, and flushing and locking), especially
when transfer to an alternative setting (eg, home care,
ambulatory setting) is planned.43,242
L. Education of facility administrators is necessary to en-
sure adequate funding and implementation of CLABSI
prevention.242 Additionally, the goal of zero tolerance
for CLABSI may be set by the chief officers of an in-
stitution;245 however, whether this goal can be reached
depends on a number of factors.
III. Execute
A. Consider the use of quality improvement methodolo-
gies, such as Lean Six Sigma, Comprehensive Unit-
Based Safety Program, Team STEPPS, Plan-Do-Study-
Act, and the like, to structure prevention efforts.
Various performance improvement tools can be used,
such as dashboards and score cards, to share data with
stakeholders.
B. Standardize care processes. This can be done through
implementation of guidelines, bundles, and protocols
that address both insertion and maintenance of central
lines. Consider conducting structured daily multidis-
ciplinary rounds. During rounds, discuss whether the
patient still requires the central line, patient goals for
the day, and potential barriers or safety issues.217 Em-
power staff to report process defects or barriers to im-
plementation encountered to appropriate leadership.
This can facilitate rapid intervention and process im-
provement. Assign accountability for adherence to spe-
cific departments or functions.
C. Create redundancy. Build redundancy or independent
checks into the care delivery process to increase staff
compliance. This can be done by incorporating visual
cues as reminders for proper procedures. Implement a
line insertion and line maintenance checklist both in-
side and outside ICUs. Consider the use of screen-saver
messages, posters, banners, fact sheets, preprinted order
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sets, pocket cards, and the like to educate and serve as
reminders for staff.217,218
D. Consider participating in a CLABSI reduction collab-
orative. Collaboratives provide an organization with the
opportunity to discover and share best practices and
utilize comparative outcome data.
IV. Evaluate
A. Multidisciplinary teams should be used to form quality
improvement collaboratives to set goals and identify
the key factors to be measured. This team should have
representatives from administration, all professions,
and clinical nursing units.246,247 These teams may rep-
resent one hospital or many different hospitals.54,248,249
B. Evaluation involves both process and outcome mea-
surement.246 Differences between age groups should
also be considered (eg, neonates, pediatrics, and
adults).54,249,250
C. Process measurement includes but is not limited to
compliance with insertion bundles, CVC utilization by
insertion site or type (eg, femoral catheters vs other
CVC sites; PICCs vs centrally inserted lines), the con-
dition of CVC dressing and timely dressing changes,
and integrity and appropriate management of needle-
less connectors, other add-on devices, and intravenous
administration sets.43,251,252 Device utilization is defined
as the number of catheter-days divided by the number
of patient-days.245
D. Establish baseline compliance with evidence-based
practices for line maintenance, such as the presence of
clean and intact dressings.
E. Outcome measurement is the incidence rate of CLABSI
and other infections associated with all types of vascular
access devices (eg, exit-site infection, suppurative throm-
bophlebitis). Consider reporting CLABSI rates as SIR.
F. Process and outcome data should be linked to initial
and ongoing competency assessment. Initial compe-
tency should be assessed at employment, after orien-
tation, and with the introduction of new equipment or
technology. Ongoing competency assessment is deter-
mined by process and outcome data with the facility
deciding the frequency for repeated competency
assessment.43
G. Measurement of education outcomes is needed on sev-
eral levels. The learner’s satisfaction with the program
is assessed by completion of the evaluation form im-
mediately following completion of the program. This
form also includes the learner’s self-assessment of
achieving the learning objectives. The next level is mea-
suring the change in learner’s knowledge, most often
accomplished by comparison of scores on written pre-
and posttests. The third level is to measure the actual
change in behavior in clinical practice following the
completion of the program. Using only the first and
second levels of measurement will not ensure that a
change in clinical behavior will occur.
Numerous factors affect CLABSI surveillance, in-
cluding CVC type, CLABSI definition, blood culturing
practices and written policies, laboratory practices, and
staff attitudes and beliefs. Standardization of these fac-
tors facilitates benchmarking within and between or-
ganizations. Additionally, variations in these determi-
nants could impact publicly reported CLABSI rates and
influence reimbursement for hospital-acquired con-
ditions.32,247
H. Surveillance for CLABSI outside the ICU is becoming
more prevalent, especially with increasing use of elec-
tronic methods for data collection.253,254
I. Feedback to all healthcare staff is critical for the success
of any evaluation program. Unit-based recognition of
achievement of low CLABSI rates or the length of time
between CLABSI events is a useful method to encourage
staff involvement. The goals for improvement should be
clearly and frequently articulated. Audit compliance
with completion of insertion checklists and share this
data with the staff. Other forms of feedback include
periodic (eg, monthly, quarterly) communication (eg,
e-mail messages, written reports) of process measure-
ment data: posters, reports, or other forms of com-
munication with graphs showing cumulative compliance
with process measures.245,250,255,256
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